TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05001997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose free probiotic yogurt
Description: Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose free probiotic yogurt
Description: Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
Study: NCT05168709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Study: NCT05763654

Intervention type: DEVICE
Intervention: Linovera emulsion
Description: Apply Linovera emulsion in clinical routine
Study: NCT04963946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop ACA
Description: discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACA Continuation
Description: continuation of acalabrutinib at the same dose
Study: NCT04031573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via the enteral route, every 12 hours.
Study: NCT05195892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of alpelisib granule at 50 mg in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of alpelisib granule at 50 mg in fasted state
Study: NCT05887206

Intervention type: OTHER
Intervention: Collection of datas
Description: The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
Study: NCT06242704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory
Description: A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
Study: NCT04314388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Outdoor Walking Rehabilitation Programme
Description: Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.

Intervention type: OTHER
Group type: OTHER
Intervention: Control: The light Stretches Programme
Description: Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
Study: NCT05194475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermogenic Ready-to-drink Beverage
Description: Thermogenic ready-to-drink beverage, which will be ingested by the participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ready-to-drink Beverage
Description: Placebo ready-to-drink beverage, which will be ingested by the participant.
Study: NCT06002646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite Solution
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
Study: NCT06226298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiaxi postural hammock
Description: Lie in the Xiaxi postural hammock for 10 minutes for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga mat
Description: Lie in the Yoga mat for 10 minutes for 5 days.
Study: NCT05387694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombotic risk assessment
Description: Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
Study: NCT06474650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet
Description: Single-dose of 30 mg of LPM3770164 sustained release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet
Description: Single-dose of 30 mg of LPM3770164 sustained release tablet
Study: NCT06098716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Regulation
Description: How to plan for Family PA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Regulation
Description: How to plan for Family PA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity & Family functioning
Description: Increasing self-identity to increase parental support of child PA \& family functioning
Study: NCT05825651

Intervention type: OTHER
Intervention: no interventions
Description: This is an observational study without any intervention.
Study: NCT05172791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship messaging
Description: Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship messaging
Description: Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
Study: NCT05303233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective tibial nerve block
Description: The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK
Description: The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
Study: NCT05935033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablet
Study: NCT06444828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative
Description: Non-operative treatment versus operative treatment (surgery)
Study: NCT06246149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Tebentafusp will be administered weekly i.v.
Study: NCT06363526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital respiratory intervention program
Description: A 4 times a week for a period of 5 weeks will be done, for a duration of 55-60 minutes (20 sessions), with an intensity adapted to the characteristics of each participant. Moreover, an intervention program will be used based on respiratory muscle training exercises, upper limb strength work, yoga, diaphragmatic awareness exercises, always trying to do them through the use of games, and even try to include exercises that use motor imagery.~The intervention program is carried out and stimulated through videos and therapeutic teaching to the caregivers in the first evaluation session, as well as as well as with a weekly follow-up using WhatsApp or Zoom as forms of communication, or a telephone call to ensure correct follow-up of the intervention program. Moreover, YouTube videos, own videos prepared by the physiotherapy will be used to help optimally resolve doubts that arise when carrying out the program by video call.
Study: NCT05606770

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Exercise
Description: Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Physical Activity
Description: The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
Study: NCT05281900

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: Shoulder impingement and instability tests and shoulder normal range of motion measurement.
Study: NCT06254755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical thrombectomy
Description: mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
Study: NCT05281900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC measurements
Description: For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank
Study: NCT06438575

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Xpert® Xpress MVP test
Description: The Xpert® Xpress MVP is an FDA-cleared point-of-care test for vaginitis diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Usual Care
Description: Usual methods used by the healthcare provider for vaginitis diagnosis
Study: NCT05456633

Intervention type: DEVICE
Intervention: Capri Cervical Static
Description: When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.

Intervention type: OTHER
Intervention: CAPRI Static Expandable
Description: When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.

Intervention type: DEVICE
Intervention: Capri Thoracolumbar
Description: Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
Study: NCT06096298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 bread
Description: Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control bread
Description: Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
Study: NCT05821075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 60mg tablet once daily for 5 days then tapering dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 60mg tablet once daily for 5 days then tapering dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: intramuscular Cerebrolysin 10 mg daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: intramuscular Cerebrolysin 10 mg daily for 3 weeks
Study: NCT06396013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment
Description: Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use.
Study: NCT05816759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D744, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D744, D150
Description: QD, PO
Study: NCT05172830

Intervention type: DEVICE
Intervention: Ovation Alto™ Abdominal Stent Graft System
Description: Single occurrence permanent implantation of AAA device
Study: NCT05140811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 is intravenously once a week, every 28 days for a treatment cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Study: NCT04341558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family supplemented patient monitoring
Description: Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
Study: NCT06254755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.